Key result
Haemoglobin A1c as a diagnostic criterion for diabetes remains controversial, with ongoing debate regarding its measurement, reporting, and overall clinical utility.
This review summarizes the controversies and evidence surrounding the WHO's recommendation to use HbA1c for diagnosing diabetes.
Persistent controversy over HbA1c diabetes diagnosis warrants clinical caution; leaves open standardization and validation needs.
Haemoglobin A 1c (HbA 1c ) has recently been adopted by the World Health Organization into its recommended criteria for diabetes diagnosis. Much debate continues regarding the relative benefits and potential disadvantages surrounding the use of HbA 1c for this purpose. There is a lack of consensus as to whether this alteration to the definition of diabetes is a step forward or whether it could add further confusion and ambiguity to the debate on the method and criteria for the diagnosis of this globally important disease. This review provides a comprehensive overview of the current issues surrounding how HbA 1c is measured and reported; and of the evidence for and against its use in diagnosis.
No takes yet. Share an insight, caveat, or question.
Hare et al. (2011) conducted a review in Diabetes. Haemoglobin A1c (HbA1c) for diagnosis was evaluated. Haemoglobin A1c as a diagnostic criterion for diabetes remains controversial, with ongoing debate regarding its measurement, reporting, and overall clinical utility.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: